Alnylam reiterates 2026 TTR sales guidance of $4.4B-$4.7B while expanding TRITON-CM enrollment to about 1,750
Alnylam Pharmaceuticals, Inc. · PHARMACEUTICAL PREPARATIONS · Now $295.63
-8.0% in 7d after detection
Post-detection moves
1h
—
1d
-4.3%
3d
-2.7%
7d
-8.0%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS